Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Compare

498 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RYTM Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Rhythm

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RYTM Stock 12 Month Forecast

Average Price Target

$83.42

▲(32.98%Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $83.42 with a high forecast of $94.00 and a low forecast of $72.00. The average price target represents a 32.98% change from the last price of $62.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","95":"$95","49.25":"$49.3","64.5":"$64.5","79.75":"$79.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$83.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,49.25,64.5,79.75,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.66,65.99384615384615,68.3276923076923,70.66153846153846,72.99538461538461,75.32923076923076,77.66307692307691,79.99692307692308,82.33076923076922,84.66461538461539,86.99846153846153,89.3323076923077,91.66615384615385,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.66,65.17999999999999,66.7,68.22,69.74,71.26,72.78,74.3,75.82,77.34,78.86,80.38,81.9,{"y":83.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.66,64.30153846153846,64.94307692307692,65.58461538461538,66.22615384615385,66.86769230769231,67.50923076923077,68.15076923076923,68.79230769230769,69.43384615384615,70.07538461538462,70.71692307692308,71.35846153846154,{"y":72,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.68,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.67,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$94.00

Average Price Target$83.42

Lowest Price Target$72.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$69

Hold

10.00%

Upside

Reiterated

06/05/25

Rhythm Pharmaceuticals' overall stock score reflects strong technical momentum and positive earnings call insights, which are tempered by financial performance challenges and valuation concerns. The company's strategic advancements and robust pipeline position it well for future growth, but profitability remains a key challenge.

Derek ArchilaWells Fargo

Wells Fargo

$80→$91

Buy

45.07%

Upside

Reiterated

06/26/25

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Thermo Fisher (TMO)

Jonathan WollebenCitizens JMP

Citizens JMP

$84

Buy

33.91%

Upside

Reiterated

06/26/25

Citizens JMP reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $84.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).

Michael UlzMorgan Stanley

Morgan Stanley

$80

Buy

27.53%

Upside

Reiterated

06/04/25

Buy Rating for Rhythm Pharmaceuticals: Promising Outlook for Bivamelagon in Treating Hypothalamic Obesity

Dennis DingJefferies

Jefferies

$80

Buy

27.53%

Upside

Initiated

06/04/25

Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Promising Pipeline and Strategic Developments

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$78→$94

Buy

49.85%

Upside

Reiterated

05/29/25

Rhythm Pharmaceuticals: Promising Growth Potential with Setmelanotide and Strategic Pipeline Advancements

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$70→$80

Buy

27.53%

Upside

Reiterated

05/23/25

H.C. Wainwright Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Whitney IjemCanaccord Genuity

Canaccord Genuity

$92

Buy

46.66%

Upside

Reiterated

05/07/25

Robust Pipeline and Regulatory Progress Bolster Buy Rating for Rhythm Pharmaceuticals

Joseph StringerNeedham

Needham

$66→$72

Buy

14.78%

Upside

Reiterated

05/07/25

Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Promising Developments and Future Growth Potential

Phil NadeauTD Cowen

TD Cowen

$65→$85

Buy

35.50%

Upside

Reiterated

05/07/25

Positive Outlook for Rhythm Pharmaceuticals Amid Strong Imcivree Demand and Promising Phase III Trial Results

Tazeen AhmadBank of America Securities

Bank of America Securities

$68→$73

Buy

16.37%

Upside

Reiterated

05/07/25

Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Promising Outlook for Setmelanotide and Strong Growth Prospects

Leland GershellOppenheimer

Oppenheimer

$76

Buy

21.15%

Upside

Reiterated

04/08/25

Oppenheimer reiterates Outperform Rating on Rhythm Pharmaceuticals (RYTM)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $76.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).

Seamus FernandezGuggenheim

Guggenheim

$94

Buy

49.85%

Upside

Reiterated

04/07/25

Guggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Corinne JohnsonGoldman Sachs

Goldman Sachs

$59→$66

Buy

5.21%

Upside

Reiterated

12/05/24

Rhythm Pharmaceuticals (RYTM) PT Raised to $66 at Goldman SachsGoldman Sachs analyst Corinne Jenkins raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $66.00 (from $59.00) while maintaining a Buy rating.

Michael HigginsLadenburg Thalmann & Co.

Ladenburg Thalmann & Co.

$70

Buy

11.59%

Upside

Reiterated

08/07/24

Strong Financial Health and Expanding Market Presence Solidify Buy Rating for Rhythm Pharmaceuticals

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$69

Hold

10.00%

Upside

Reiterated

06/05/25

Derek ArchilaWells Fargo

Wells Fargo

$80→$91

Buy

45.07%

Upside

Reiterated

06/26/25

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Thermo Fisher (TMO)

Jonathan WollebenCitizens JMP

Citizens JMP

$84

Buy

33.91%

Upside

Reiterated

06/26/25

Michael UlzMorgan Stanley

Morgan Stanley

$80

Buy

27.53%

Upside

Reiterated

06/04/25

Buy Rating for Rhythm Pharmaceuticals: Promising Outlook for Bivamelagon in Treating Hypothalamic Obesity

Dennis DingJefferies

Jefferies

$80

Buy

27.53%

Upside

Initiated

06/04/25

Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Promising Pipeline and Strategic Developments

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$78→$94

Buy

49.85%

Upside

Reiterated

05/29/25

Rhythm Pharmaceuticals: Promising Growth Potential with Setmelanotide and Strategic Pipeline Advancements

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$70→$80

Buy

27.53%

Upside

Reiterated

05/23/25

H.C. Wainwright Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Whitney IjemCanaccord Genuity

Canaccord Genuity

$92

Buy

46.66%

Upside

Reiterated

05/07/25

Robust Pipeline and Regulatory Progress Bolster Buy Rating for Rhythm Pharmaceuticals

Joseph StringerNeedham

Needham

$66→$72

Buy

14.78%

Upside

Reiterated

05/07/25

Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Promising Developments and Future Growth Potential

Phil NadeauTD Cowen

TD Cowen

$65→$85

Buy

35.50%

Upside

Reiterated

05/07/25

Positive Outlook for Rhythm Pharmaceuticals Amid Strong Imcivree Demand and Promising Phase III Trial Results

Tazeen AhmadBank of America Securities

Bank of America Securities

$68→$73

Buy

16.37%

Upside

Reiterated

05/07/25

Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Promising Outlook for Setmelanotide and Strong Growth Prospects

Leland GershellOppenheimer

Oppenheimer

$76

Buy

21.15%

Upside

Reiterated

04/08/25

Seamus FernandezGuggenheim

Guggenheim

$94

Buy

49.85%

Upside

Reiterated

04/07/25

Guggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Corinne JohnsonGoldman Sachs

Goldman Sachs

$59→$66

Buy

5.21%

Upside

Reiterated

12/05/24

Michael HigginsLadenburg Thalmann & Co.

Ladenburg Thalmann & Co.

$70

Buy

11.59%

Upside

Reiterated

08/07/24

Strong Financial Health and Expanding Market Presence Solidify Buy Rating for Rhythm Pharmaceuticals

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rhythm Pharmaceuticals

1 Month

xxx

Success Rate

13/16 ratings generated profit

Average Return

+8.54%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 81.25% of your transactions generating a profit, with an average return of +8.54% per trade.

3 Months

xxx

Success Rate

12/16 ratings generated profit

Average Return

+18.58%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +18.58% per trade.

1 Year

Corinne JohnsonGoldman Sachs

Success Rate

16/16 ratings generated profit

Average Return

+60.27%

reiterated a buy rating 7 months ago

Copying Corinne Johnson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +60.27% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+114.25%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +114.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYTM Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RYTM has received 31 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 83.42.

Each month's total comprises the sum of three months' worth of ratings.

RYTM Financial Forecast

RYTM Earnings Forecast

Next quarter’s earnings estimate for RYTM is -$0.64 with a range of -$0.81 to -$0.49. The previous quarter’s EPS was -$0.81. RYTM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year RYTM has Outperformed its overall industry.

RYTM Sales Forecast

Next quarter’s sales forecast for RYTM is $43.72M with a range of $41.50M to $47.30M. The previous quarter’s sales results were $32.70M. RYTM beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year RYTM has Outperformed its overall industry.

RYTM Stock Forecast FAQ

What is RYTM’s average 12-month price target, according to analysts?

Based on analyst ratings, Rhythm Pharmaceuticals’s 12-month average price target is 83.42.

What is RYTM’s upside potential, based on the analysts’ average price target?

Rhythm Pharmaceuticals has 32.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RYTM a Buy, Sell or Hold?

Rhythm Pharmaceuticals has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Rhythm Pharmaceuticals’s price target?

The average price target for Rhythm Pharmaceuticals is 83.42. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $94.00 ,the lowest forecast is $72.00. The average price target represents 32.98% Increase from the current price of $62.73.

What do analysts say about Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of RYTM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

RYTM Analyst Ratings

RYTM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rhythm Pharmaceuticals

RYTM Analyst Recommendation Trends

RYTM Financial Forecast

RYTM Earnings Forecast

RYTM Sales Forecast

RYTM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts